Screening for NAFLD—Current Knowledge and Challenges

Forlano, Roberta; Sigon, Giordano; Mullish, Benjamin H.; Yee, Michael; Manousou, Pinelopi

doi:10.3390/metabo13040536

Cited by 8 publications

(6 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first exploratory cross-sectional study evaluating the association between moderate-to-severe AD and NAFLD. The novel finding of our cross-sectional study was that the prevalence of NAFLD detected via ultrasonography in adult patients with moderate-to-severe AD was 24.1%, similar to that observed in patients with melanoma in situ (considered as the control group), and to that already reported in the general adult population [ 10 , 11 , 12 , 13 ]. The main reasons for which we chose patients with melanoma in situ as the control group are the following: (a) they represent a patient group with a non-inflammatory skin disease, different to psoriasis and AD; (b) based on the current knowledge, it is unlikely that melanoma in situ can significantly influence the development and progression of NAFLD.…”

Section: Discussionsupporting

confidence: 87%

“…Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases worldwide, with an estimated global prevalence of around 30% in adults in the general population [ 10 , 11 , 12 , 13 ]. NAFLD is characterized by an accumulation of fat in the liver, and is strongly associated with insulin resistance and metabolic syndrome features [ 14 , 15 , 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis

Maurelli,

Gisondi,

Bellinato

et al. 2023

JCM

View full text Add to dashboard Cite

Background: There are no published studies on the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with atopic dermatitis (AD). Objectives: To estimate the prevalence of NAFLD (assessed via liver ultrasonography) in adults with moderate-to-severe AD. Methods: We performed a retrospective, cross-sectional, observational study including adult patients affected by moderate-to-severe AD, moderate-to-severe chronic plaque psoriasis, or a previous diagnosis of thin melanoma in situ (considered as the control group) who attended the Verona University Hospital between January 2022 and April 2023. Fatty liver was assessed via liver ultrasonography. Results: A total of 144 adults with AD, 466 with chronic plaque psoriasis, and 99 with thin melanoma were included. The prevalence rates of ultrasound-detected NAFLD among patients with in situ melanoma, those with moderate-to-severe AD, and those with moderate-to-severe chronic plaque psoriasis were 23.2% (23 out of 99), 24.1% (36 out of 144), and 49.8% (228 out of 466), respectively (p < 0.01). Logistic regression analysis revealed that being of male sex, a higher age, a higher body mass index, and psoriasis were independently associated with NAFLD, whereas AD was not. Conclusions: Our findings show that the prevalence of ultrasound-detected NAFLD in patients with moderate-to-severe AD was comparable to that of patients with a previous diagnosis of in situ melanoma. It is plausible to hypothesize that the Th2-type inflammation typically characterizing AD is not a risk factor for NAFLD. Patients with moderate-to-severe psoriasis, but not those with AD, should be screened for NAFLD and other metabolic comorbidities.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis

Maurelli,

Gisondi,

Bellinato

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Moreover, personalized medicine can play a significant role in managing NAFLD including metabolic syndrome [40]. Given that NAFLD affects more than a quarter of the population, it is impractical to screen everyone [41]. A recent study demonstrated that specific genetic variants, such as patatin-like phospholipase domaincontaining 3 (PNPLA3), or biomarkers, can possibly be used to predict the progression of NAFLD [42][43][44].…”

Section: Discussionmentioning

confidence: 99%

The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the Elderly in the Asia-Pacific Region: An Insight from the Global Burden of Disease Study 2019

Danpanichkul,

Kongarin,

Permpatdechakul

et al. 2023

JCM

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) represents a significant health threat worldwide. The aging population and a rise in metabolic syndrome in Asia might influence the epidemiology of NAFLD among the elderly. However, there is a lack of understanding of the burden and recommendations for NAFLD in this group. Our study sought to investigate the trends in the NAFLD burden among the elderly in the Asia-Pacific region. We employed data from the Global Burden of Disease 2019 study for an in-depth analysis of the prevalence and disability-adjusted life years (DALYs) along with age-standardized rate (ASR) associated with NAFLD in elderly populations (age 65–89 years) across the Asia-Pacific region, including the Southeast Asia (SEA) and Western Pacific (WP) regions, from 2010 to 2019. This study also examined the trends and disparities in NAFLD burden across different nations and sexes. In 2019, there were over 120 million cases of NAFLD in the elderly in the Asia-Pacific region. The ASR of prevalence was higher in SEA compared to WP (36,995.37 vs. 32,821.78 per 100,000). ASR of prevalence increased with annual percentage change (APC) +0.95% in the WP while it increased by +0.87% in SEA. During the study period, the ASR of DALYs decreased in SEA (APC −0.41%) but remained stable in the WP region. The burden of NAFLD in the elderly population in Asia-Pacific has increased, underscoring the timely intervention to tackle this high and rising burden.

show abstract

“…This lack of knowledge may lead to inconsistent screening practices. 103 104 105 106 Disease awareness and physician knowledge could be improved after the introduction of the new diagnostic criteria, which are more defined and simplified. Additionally, this highlights the need for further education and training for PCP on disease diagnosis and management.…”

Section: Challenges In the Well-established Metabolic Dysfunction-ass...mentioning

confidence: 99%

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

El-Kassas,

Awad,

Elbadry

et al. 2024

Semin Liver Dis

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a healthcare challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the healthcare system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care, including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed model of care.

show abstract

Screening for NAFLD—Current Knowledge and Challenges

Cited by 8 publications

References 93 publications

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis

The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the Elderly in the Asia-Pacific Region: An Insight from the Global Burden of Disease Study 2019

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Contact Info

Product

Resources

About